Recruiting soon

REBUILDBody Composition and Muscle Function in Type 2 Diabetes on GLP-1RA Therapy

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study observes how GLP-1RA therapy affects body composition and muscle function in individuals with Type 2 Diabetes.

What is being collected

Data Collection

Collected from today forward - Prospective
Who is being recruted

Diabetes Mellitus+3

+ Diabetes Mellitus, Type 2

+ Endocrine System Diseases

Over 18 Years
+10 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: October 2025
See protocol details

Summary

Principal SponsorKristin Clemens
Study ContactHeather LaPier, BSc
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: October 1, 2025

Actual date on which the first participant was enrolled.

This study aims to understand how certain diabetes medications, like semaglutide (Ozempic) and tirzepatide (Mounjaro), affect older adults with type 2 diabetes, especially those at risk of losing muscle mass and strength. The research focuses on patients with additional health challenges like obesity, kidney disease, or heart conditions. These medications are known for helping control blood sugar and promoting weight loss, but there are concerns about potential muscle loss, which can lead to frailty and other serious health issues. By understanding the effects of these drugs on muscle and bone health, this study seeks to provide valuable insights that could enhance treatment plans and improve the quality of life for older adults with diabetes. Participants in the study will start taking one of the specified diabetes medications, and researchers will monitor changes in their body composition, muscle mass, and physical function. Advanced imaging techniques like MRI will be used instead of traditional methods to provide a more detailed picture of muscle and fat distribution. The study will also assess muscle strength and function, which are crucial for predicting potential health outcomes. The findings aim to help healthcare providers make better-informed decisions when prescribing these medications, ensuring that patients maintain muscle health and reduce risks of falls or fractures.

Official TitleResearch on Effects of Drugs on Body Composition and Function With Imaging in Diabetes
Principal SponsorKristin Clemens
Study ContactHeather LaPier, BSc
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

20 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Diabetes MellitusDiabetes Mellitus, Type 2Endocrine System DiseasesMetabolic DiseasesNutritional and Metabolic DiseasesGlucose Metabolism Disorders

Criteria

4 inclusion criteria required to participate
Be at least 18 years old

Have type 2 diabetes

Have recently been started on semaglutide or tirzapatide under the care of a physician

Be able to speak and read English

6 exclusion criteria prevent from participating
Are pregnant or breastfeeding

Are unable to perform functional tests

Are unable to provide informed consent

Have any contraindication to PET/CT scan

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available.
Recruiting soonNo study centers